> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CDER Office of Hematology, Oncology Products Reorganized
- URL: https://www.fdaweb.com/cder-office-of-hematology-oncology-products-reorganized/
- Published: 2019-11-06T12:00:00.000Z
- Updated: 2026-09-14T15:52:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145438

The CDER Office of Hematology and Oncology Products (OHOP) has been reorganized as the Office of Oncologic Diseases (OOD). An agency [announcement](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-office-hematology-oncology-products-reorganizes-renamed-office-oncologic-diseases?ref=fdaweb.com) says that OHOP director **Richard Pazdur** has been named acting director of OOD. Pazdur also directs the FDA Oncology Center of Excellence that was established in 2017 to help expedite the development of oncology and hematology medical products and support an integrated approach in the clinical evaluation of drugs, biologics, and medical devices to treat cancer.

The announcement shows the six divisions in the new OOD and explains their general responsibilities and activities.